Fig. 6

Schematic diagram of ILA830 treatment effects on PD symptom improvement via muscle metabolic alterations and brain recovery in a PD mouse model. ILA at the GB34 acupoint using an 830 nm wavelength stimulates the muscle layer, inducing therapeutic effects in the MPTP-induced PD mouse model. This targeted stimulation leads to significant alterations in muscle metabolites, such as glucose and galactose, enhancing systemic energy availability. These peripheral metabolic changes are proposed to influence the brain, leading to anti-inflammatory and anti-apoptotic effects. Consequently, ILA treatment contributes to the improvement of both motor and non-motor symptoms observed in PD